Everolimus

Common brands: Afinitor Disperz, Afinitor, Zortress, Torpenz, Yulithira

Top reporter: Novartis Pharmaceuticals Corporation

Kinase Inhibitor [EPC]mTOR Inhibitor Immunosuppressant [EPC]Aromatase Inhibitor [EPC]Corticosteroid [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]
50,179
Total Reports
19,720
Serious Reports
10,805
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.53%)

Patient Demographics

Male
18,659
Female
27,212

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Everolimus.

# Reaction Reports % of Total
1 DEATH 6,333
9.9%
2 MALIGNANT NEOPLASM PROGRESSION 4,640
7.3%
3 DIARRHOEA 4,024
6.3%
4 FATIGUE 3,778
5.9%
5 STOMATITIS 3,175
5.0%
6 NAUSEA 2,815
4.4%
7 DYSPNOEA 2,631
4.1%
8 DRUG INEFFECTIVE 2,326
3.6%
9 PYREXIA 2,128
3.3%
10 VOMITING 2,113
3.3%
11 DECREASED APPETITE 2,102
3.3%
12 RASH 1,971
3.1%
13 WEIGHT DECREASED 1,926
3.0%
14 COUGH 1,888
3.0%
15 ASTHENIA 1,880
2.9%
16 MALAISE 1,874
2.9%
17 OFF LABEL USE 1,770
2.8%
18 PNEUMONIA 1,684
2.6%
19 PAIN 1,564
2.4%
20 DISEASE PROGRESSION 1,519
2.4%
21 ANAEMIA 1,445
2.3%
22 HEADACHE 1,356
2.1%
23 METASTASES TO LIVER 1,245
1.9%
24 PNEUMONITIS 1,188
1.9%
25 PRODUCT USE IN UNAPPROVED INDICATION 1,161
1.8%
26 ABDOMINAL PAIN 1,160
1.8%
27 DEHYDRATION 1,078
1.7%
28 GENERAL PHYSICAL HEALTH DETERIORATION 1,046
1.6%
29 NEOPLASM PROGRESSION 1,033
1.6%
30 METASTASES TO BONE 1,032
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.